Compare RLMD & MCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RLMD | MCI |
|---|---|---|
| Founded | 2004 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.8M | 378.5M |
| IPO Year | 2012 | N/A |
| Metric | RLMD | MCI |
|---|---|---|
| Price | $3.06 | $17.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.75 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 31.4K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.46% |
| EPS Growth | ★ 45.28 | N/A |
| EPS | N/A | ★ 1.82 |
| Revenue | ★ $13,070.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.98 |
| Revenue Growth | ★ 154.83 | N/A |
| 52 Week Low | $3.07 | $16.21 |
| 52 Week High | $8.00 | $21.33 |
| Indicator | RLMD | MCI |
|---|---|---|
| Relative Strength Index (RSI) | 37.32 | 45.33 |
| Support Level | N/A | $17.28 |
| Resistance Level | $3.55 | $18.18 |
| Average True Range (ATR) | 0.43 | 0.44 |
| MACD | -0.04 | 0.08 |
| Stochastic Oscillator | 4.05 | 39.52 |
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.